albumin Archives - Critical Care Science (CCS)
Abstract
Rev Bras Ter Intensiva. 2011;23(1):87-95
DOI 10.1590/S0103-507X2011000100014
Human albumin has been used as a therapeutic agent in intensive care units for more than 50 years. However, clinical studies from the late 1990s described possible harmful effects in critically ill patients. These studies' controversial results followed other randomized controlled studies and meta-analyses that showed no harmful effects of this colloid solution. In Brazil, several public and private hospitals comply with the Agência Nacional de Vigilância Sanitária (the Brazilian Health Surveillance Agency) recommendations for appropriate administration of intravenous albumin. This review discusses indications for albumin administration in critically ill patients and analyzes the evidence for metabolic and immunomodulatory effects of this colloid solution. We also describe the most significant studies from 1998 to the present time; these reveal an absence of incremental mortality from intravenous albumin administration as compared to crystalloid solutions. The National Health Surveillance Agency indications are discussed relative to the current body of evidence for albumin use in critically ill patients.
Abstract
Rev Bras Ter Intensiva. 2011;23(1):87-95
DOI 10.1590/S0103-507X2011000100014
Human albumin has been used as a therapeutic agent in intensive care units for more than 50 years. However, clinical studies from the late 1990s described possible harmful effects in critically ill patients. These studies' controversial results followed other randomized controlled studies and meta-analyses that showed no harmful effects of this colloid solution. In Brazil, several public and private hospitals comply with the Agência Nacional de Vigilância Sanitária (the Brazilian Health Surveillance Agency) recommendations for appropriate administration of intravenous albumin. This review discusses indications for albumin administration in critically ill patients and analyzes the evidence for metabolic and immunomodulatory effects of this colloid solution. We also describe the most significant studies from 1998 to the present time; these reveal an absence of incremental mortality from intravenous albumin administration as compared to crystalloid solutions. The National Health Surveillance Agency indications are discussed relative to the current body of evidence for albumin use in critically ill patients.
Abstract
Rev Bras Ter Intensiva. 2007;19(2):192-196
DOI 10.1590/S0103-507X2007000200009
BACKGROUND AND OBJECTIVES: Although has been available for clinical administration for over 50 years, the use of human albumin keep being a controversial and hotly debated and it is theme of many papers in medical journals. The opinions and justifications for the use of albumin are huge and only more recently were published betters papers leaded to appraisal more significant outcomes as the impact in the mortality of the treat patients. The objectives of this paper are: to check the albumin indications, to compare them with Agência Nacional de Vigilância Sanitária (ANVISA) guideline of 2004, recent scientific researches and to estimate the total cost of the product. METHODS: Analysis of the justifications of human albumin use in 206 requests, of 2005, identified in Hospital Universitário Antonio Pedro (HUAP) data base. RESULTS: A great amount of albumin was used without scientific justifications, generating financial expenditures of thousand of reais, but whose impact on the health of the patients is impossible to be evaluated in this work. CONCLUSIONS: Although the great discussion and many papers about this theme, the albumin is still use in an intense and unrestricted way in this teaching hospital.
Abstract
Rev Bras Ter Intensiva. 2007;19(2):192-196
DOI 10.1590/S0103-507X2007000200009
BACKGROUND AND OBJECTIVES: Although has been available for clinical administration for over 50 years, the use of human albumin keep being a controversial and hotly debated and it is theme of many papers in medical journals. The opinions and justifications for the use of albumin are huge and only more recently were published betters papers leaded to appraisal more significant outcomes as the impact in the mortality of the treat patients. The objectives of this paper are: to check the albumin indications, to compare them with Agência Nacional de Vigilância Sanitária (ANVISA) guideline of 2004, recent scientific researches and to estimate the total cost of the product. METHODS: Analysis of the justifications of human albumin use in 206 requests, of 2005, identified in Hospital Universitário Antonio Pedro (HUAP) data base. RESULTS: A great amount of albumin was used without scientific justifications, generating financial expenditures of thousand of reais, but whose impact on the health of the patients is impossible to be evaluated in this work. CONCLUSIONS: Although the great discussion and many papers about this theme, the albumin is still use in an intense and unrestricted way in this teaching hospital.